Get started

PHARMA

Novo Nordisk hit my target this week and I have started to buy The head and shoulders pattern successfully played out, with OMXCOP:NOVO_B reaching my full target at 670. Check out my original post: The stock experienced a significant drop, falling as much as 27% on the Friday before Christmas. This was triggered by test results for their obesity drug, CagriSema, which showed patient weight loss of 22.7% - below the anticipated 25%. I believe this reaction is an overcorrection and have taken advantage of this rare opportunity to purchase OMXCOP:NOVO_B , first at 680 and again at 600. I now plan to hold patiently, expecting Novo Nordisk to reach new all-time highs in the coming years.
OMXCOP:NOVO_BLong
by madsroland
Novartis | NVS | Long at $99.00As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is nearing the historical simple moving average line and may be poised for another move up. However, entry into the lower $90's or even $80's is still not off the table and, in my view, a great opportunity. Thus, at $99.00, NYSE:NVS is in a personal buy zone. Target #1 = $110.00 Target #2 = $120.00
NYSE:NVSLong
by WorthlessViews
Aarti Drugs - Key Levels to WatchAarti Drugs - Key Levels to Watch 🔍 Aarti Drugs has shown some recovery after restoring production at its Tarapur unit, as per recent filings. Here’s the technical outlook: 1.Fibonacci Retracement Levels: Resistance at 0.618 (₹593) and 0.5 (₹676). Immediate support near 0.786 (₹476). 2.Volume Profile: High activity seen between ₹450-₹500. Sustained support in this zone is crucial. 3.RSI: Current RSI shows a slight bullish divergence—monitor for a potential rebound. Levels of Interest: Upside Potential: ₹593 (618 Fib) and ₹676 (0.5 Fib). Downside Support: ₹476 (786 Fib) and ₹450 (volume support zone). Stay cautious as the stock consolidates. Monitor for clear directional moves above or below these levels.
NSE:AARTIDRUGS
by AngshumanSaikia
Natco Pharma- A multibagger?NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. The Company has also forayed into Crop health and completed state-of-the-art greenfield manufacturing facilities for agro technical and formulation products, with a total Capex spend of over INR 150 crores located in Nellore, AP. The company is making strategic investments and buying stakes in multiple companies. The management is looking keen to grow the company and reach the whole world. Some technical of the company- Return on capital employed >30 AND Debt to equity <0.1 AND Net profit preceding 12months >500 AND Net Profit latest quarter >100 This stock looks excellent for long term growth and may become a multibagger in the future. Do keep it in your watchlist and keep a sharp eye on the results. I am not a SEBI registered analyst. Please do your own analysis before investing. Do like and follow and share among your friends and family. Thank you.
NSE:NATCOPHARMLong
by ronak16125
1
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
Teva Pharmaceuticals (TEVA) Analysis Company Overview: Teva Pharmaceuticals, a global leader in generics and specialty medicines, is poised for growth as it expands its biosimilar portfolio and resolves major legal challenges. Key Catalysts: Biosimilar Launch: NYSE:TEVA plans to launch AVT04, a biosimilar to Johnson & Johnson's blockbuster drug Stelara, by February 2025. Stelara, which generates $10 billion in annual sales, presents a significant market opportunity for Teva as a lower-cost alternative. This biosimilar could drive substantial revenue growth for the company. Opioid Settlement: The resolution of the $4.3 billion opioid settlement reduces legal uncertainty and allows Teva to focus on business expansion. This development provides a clearer path forward for the company’s financial health. Operational Improvements: With improved supply chains and enhanced gross margins, Teva is positioned to strengthen profitability. This operational efficiency will be crucial in boosting the company's bottom line as it rolls out new products. Investment Outlook: Bullish Outlook: We are bullish on TEVA if it holds above the $15.50-$16.00 range. Upside Potential: The upside target for Teva Pharmaceuticals is set at $23.00-$24.00, driven by the upcoming biosimilar launch, legal clarity, and improved operational performance. 💊 Teva Pharmaceuticals—biosimilar potential and legal resolution set to unlock growth! #TEVA #Pharma 🚀📈
NYSE:TEVALong
by Richtv_official
Cup And Handle formation in Marksans Pharma on Monthly CandlesA Cup and Handle Pattern seems to be forming in Marksans Pharma on Monthly basis which explains the recent up move. Good Buying Price would be at 166 (If Someone has bought it at this price can hold it) Other Buying Opportunity can be Below 260 SL can be marked at 106 Targets Can be Target 1 can be around 290 to 300 Target 2 can be around 390 to 400 Caution: This is not a stock trading Advice or Tip, it's just for learning purposes I am not a professional trader or a SEBI registered advisor. Please don't consider this as an advice and make your own analysis before investing. Thankyou!
NSE:MARKSANSLong
by jagarsoshi
Axsome Therapeutics - A Pennant Primed to RiseAxsome - NASDAQ:AXSM ✅In position since Feb 2023 with average price $50.00 per share. This is a long term 3 - 5 year hold. ✅ Current unrealized gain at 75% ✅ Stop Loss set at $63.80 for 50% of the position to ensure short term gain capture ⏳We awaiting increasing levels of volume (see the green zone). Volume moving into this zone would be ideal and demonstrate increased interest ⏳The On Balance Volume (OBV) has demonstrated that is consolidates in parallel channels and when it breaks out of them it signals price direction. We can watch the OBV for direction The chart still looks great and we are sitting in a nice profit position with short term profits guaranteed by a stop. The OBV will be key to watch. I still think this company is ripe for a buy out. Background of Axsome Therapeutics AXSM are a Small Bio-Pharma company with market cap of $4.24 Billon. In August 2022 Auvelity Anti-Depressants was FDA approved & is the only rapid-acting oral medicine for MDD with labelling describing statistically significant antidepressant efficacy by one week. AXSM received Breakthrough Therapy designation from the FDA for an Alzheimer's disease drug development and are at the NDA phase for developing a drug for acute treatment of migraine. AXSM are also developing a treatment for narcolepsy and separately for fibromyalgia. All in, AXSM's offerings are building momentum. They have developed the fastest acting anti-depressant drug and are bringing it to market, and have a four other drugs in development, all of which have a large patient base. The company would be ripe for a buyout. PUKA
NASDAQ:AXSMLong
by PukaCharts
1
SWING IDEA - GLAXO SMITHKLINE PGlaxoSmithKline Pharmaceuticals , a major player in the pharmaceutical industry, is displaying technical signals that suggest a potential swing trade opportunity. Reasons are listed below : Breakthrough of Strong Resistance (1800-1900) : The 1800-1900 range was a significant resistance level. The price has broken through, retested, and is now making new highs, indicating strong bullish momentum. Breaking a 9+ Year Consolidation Phase : The stock has emerged from a consolidation phase that lasted over 9 years, signaling a potential new long-term bullish trend. Bullish Engulfing Candle on Weekly Timeframe : The recent bullish engulfing candle on the weekly chart indicates a significant shift towards bullish sentiment, engulfing the previous week's candle and suggesting further upward movement. 0.5 Fibonacci Support : The stock has found support at the 0.5 Fibonacci retracement level, reinforcing the potential for a continued bullish trend after a retracement. Increased Volumes : A noticeable increase in trading volumes confirms the strength of the price move, indicating strong investor interest and participation in the current trend. Trading at All-Time High : The stock is trading at its all-time high, suggesting strong market confidence and the potential for further gains. However, it's also important to monitor for signs of overextension or profit-taking at these levels. Target - 2940 // 3600 Stoploss - weekly close below 1950 DISCLAIMER - Decisions to buy, sell, hold or trade in securities, commodities and other investments involve risk and are best made based on the advice of qualified financial professionals. Any trading in securities or other investments involves a risk of substantial losses. The practice of "Day Trading" involves particularly high risks and can cause you to lose substantial sums of money. Before undertaking any trading program, you should consult a qualified financial professional. Please consider carefully whether such trading is suitable for you in light of your financial condition and ability to bear financial risks. Under no circumstances shall we be liable for any loss or damage you or anyone else incurs as a result of any trading or investment activity that you or anyone else engages in based on any information or material you receive through TradingView or our services. @visionary.growth.insights
NSE:GLAXOLong
by Visionary_Growth_Insights
SunPharma-Strong Buy-Swing- End of downward range? NSE:SUNPHARMA 03.07.2024 Buy above 1539 Target:1627 Stop Loss:1494 Risk-Reward: 1:2 01. Inside candle breakout in daily & Weekly 02. After big uptrend, price is getting consolidated in downward range by creating LL & LH 03. Price has rejected & found fake breakout at 200 EMA level and 50% Fibonacci level. 04. Price has failed to create LH 04 & rejected at Midway. Further it has broke channel & retracement done. 05. 20& 50 EMA rejections & about to cross over further indicating trend reversal. Happy Trading!!
NSE:SUNPHARMALong
by Swinging_Inside_the_BAR
Momentum Trading Picks - Pharma Stock Natco Pharma.This chart is very interesting as well as confusing at the same time for some people let's break it down step by step. If you see the monthly chart of Natco Pharma you will notice many patterns there like:- Cup pattern W pattern Pole and flag Pattern Volume is increasing significantly on the monthly chart Breakout already happened last week but those who are willing to take risks can still participate in it because the stop loss will be a bit on the higher side.
NSE:NATCOPHARMLong
by mittalanugrahit
Bayer (BAYN): Is the Bottom Finally Here?Since our initial analysis in November, Bayer's stock has experienced a 40% pullback. Despite missing our limit order by 2%, we have decided to enter the market now and plan to make additional purchases if the price drops further. The stock has held around the 88.2% Fibonacci retracement level. We are currently within the 50-61.8% Fibonacci extension zone for Wave 5, which aligns with our bottom outlook. Our entry strategy involves making an initial purchase now, acknowledging the recent support levels. We plan to add to our position with multiple entries if the price drops further. Our stop-loss is set wide, at an additional 44% below our entry price, to accommodate potential volatility. This is considered a long-term swing trade, with an expectation of significant upward movement once the bottom is confirmed. This could be a knife catch here so please don't cut yourself too deep.
XETR:BAYNLong
by freeguy_by_wmc